{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-029376","form_type":"8-K","ticker":"MANE","cik":"0001827635","company_name":"Veradermics, Inc","filed_at":"2026-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.032065+00:00","generated_at":"2026-05-15T00:21:49.504275+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Veradermics raises $414M in public offering and private placement to Suvretta Capital","bullets":["Closed underwritten public offering of 3,843,790 shares at $100.00 per share, gross proceeds ~$384M.","Concurrent private placement: sold pre-funded warrants for 300,000 shares to Suvretta Capital affiliates for ~$30M.","Pre-funded warrants exercisable at $0.00001/share; 9.99% ownership cap (can be increased to 19.99% with 61 days notice).","Underwriters granted 30-day option to buy up to 576,568 additional shares at $100/share.","Company subject to 90-day lock-up on future share issuances (with customary exceptions)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-029376","json":"https://secwatch.observer/filing/0001628280-26-029376.json","markdown":"https://secwatch.observer/filing/0001628280-26-029376.md","text":"https://secwatch.observer/filing/0001628280-26-029376.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/0001628280-26-029376-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/mane-20260501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:21:49.504275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c4c5b683e27f47371783fea1f4faaea2f40bea77","claim":"Veradermics, Inc entered into Purchase Agreement with certain entities affiliated with Suvretta Capital valued at approximately $30.0 million (effective 2026-04-29).","evidence_excerpt":"On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/0001628280-26-029376-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001104659-26-057460","ticker":"CLRB","company_name":"Cellectar Biosciences, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data","event_type":"other_material","sec_items":["1.01","3.02","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057460","json":"https://secwatch.observer/filing/0001104659-26-057460.json","markdown":"https://secwatch.observer/filing/0001104659-26-057460.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/tm2613728d1_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/0001628280-26-029376-index.htm","comparable_excerpt":"pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement”","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm"}},{"accession":"0001104659-26-057915","ticker":"SUJA","company_name":"SUJA LIFE, INC.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Suja Life completes IPO of 8.9M shares at $21/share; closes May 8, 2026","event_type":"other_material","sec_items":["1.01","3.02","3.03","5.03","5.02","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057915","json":"https://secwatch.observer/filing/0001104659-26-057915.json","markdown":"https://secwatch.observer/filing/0001104659-26-057915.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1934114/000110465926057915/0001104659-26-057915-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1934114/000110465926057915/tm2530822d27_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/0001628280-26-029376-index.htm","comparable_excerpt":"On May 6, 2026, Suja Life, Inc. (the “Company”) and Suja Life Holdings, L.P. (“Holdings LP”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Jefferies LLC, and William Blair & Company, L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”) relating to the initial public offering (the “IPO”) of the Company’s Class A common stock","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1934114/000110465926057915/0001104659-26-057915-index.htm"}},{"accession":"0001493152-26-022034","ticker":"AREB","company_name":"AMERICAN REBEL HOLDINGS INC","filed_at":"2026-05-08T23:59:59+00:00","headline":"American Rebel exchanges $1.77M preferred & note for ~5.97M common shares to Streeterville","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022034","json":"https://secwatch.observer/filing/0001493152-26-022034.json","markdown":"https://secwatch.observer/filing/0001493152-26-022034.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1648087/000149315226022034/0001493152-26-022034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1648087/000149315226022034/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/0001628280-26-029376-index.htm","comparable_excerpt":"Streeterville\nSeries E Preferred Exchange Agreements On\nApril 30, 2026, the Company entered into three Exchange Agreements (the “Exchanges”) with Streeterville.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1648087/000149315226022034/0001493152-26-022034-index.htm"}},{"accession":"0001104659-26-056482","ticker":"AVTX","company_name":"Avalo Therapeutics, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Avalo Therapeutics raises ~$405M in public offering; preliminary cash $82M as of March 31","event_type":"other_material","sec_items":["1.01","2.02","7.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-056482","json":"https://secwatch.observer/filing/0001104659-26-056482.json","markdown":"https://secwatch.observer/filing/0001104659-26-056482.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/0001104659-26-056482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/tm2613717d1_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/0001628280-26-029376-index.htm","comparable_excerpt":"On May 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 19,730,000 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a price to the public of $17.75 per Share, and (b) pre-funded warrants to purchase up to 1,400,000 shares of Common Stock (the “Pre-Funded Warrants”), at a price to the public of $17.749 per Pre-Funded Warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such Pre-Funded Warrant (the “Offering”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/0001104659-26-056482-index.htm"}},{"accession":"0001104659-26-057226","ticker":"GPCR","company_name":"Structure Therapeutics Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Structure Therapeutics Amends Sales Agreement to Raise ATM Capacity to $400M and Reports Q1 2026 Financials","event_type":"other_material","sec_items":["1.01","2.02","8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057226","json":"https://secwatch.observer/filing/0001104659-26-057226.json","markdown":"https://secwatch.observer/filing/0001104659-26-057226.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926057226/0001104659-26-057226-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926057226/tm2613721d1_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/0001628280-26-029376-index.htm","comparable_excerpt":"On May 7, 2026, Structure Therapeutics Inc. (the “Company”) amended and restated that certain Sales Agreement dated August 6, 2025 (the “Sales Agreement” and as amended and restated, the “Amended and Restated Sales Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co. (collectively, the “Sales Agents”), relating to the offer and sale of the Company’s American Depositary Shares (“ADSs”), each representing three ordinary shares, $0.0001 par value per ordinary share.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926057226/0001104659-26-057226-index.htm"}},{"accession":"0001493152-26-021753","ticker":"HWH","company_name":"HWH International Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"HWH enters $10M PIPE with warrants at $0.50/share; terminates Hapi Metaverse acquisition","event_type":"other_material","sec_items":["1.01","1.02","5.02","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-021753","json":"https://secwatch.observer/filing/0001493152-26-021753.json","markdown":"https://secwatch.observer/filing/0001493152-26-021753.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1897245/000149315226021753/0001493152-26-021753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1897245/000149315226021753/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/0001628280-26-029376-index.htm","comparable_excerpt":"On May 5, 2026, HWH International Inc., a Nevada corporation (the “Company”) entered into a term sheet (the “Term Sheet”) with Smart Dynamics Technology Limited, a company incorporated in the British Virgin Islands (the “Investor”), pursuant to which the Company has agreed to sell to the Investor, for an aggregate purchase price of $10,000,000","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1897245/000149315226021753/0001493152-26-021753-index.htm"}},{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/0001628280-26-029376-index.htm","comparable_excerpt":"A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm"}},{"accession":"0001683168-26-004423","ticker":"CITR","company_name":"CitroTech Inc.","filed_at":"2026-06-01T20:15:28+00:00","headline":"CitroTech exchanges all Series A Preferred for Series C Convertible; BoltRock gets board rights","event_type":"other_material","sec_items":["1.01","3.02","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 3.02, 9.01","same event type: other_material"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004423","json":"https://secwatch.observer/filing/0001683168-26-004423.json","markdown":"https://secwatch.observer/filing/0001683168-26-004423.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/894556/000168316826004423/0001683168-26-004423-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894556/000168316826004423/citro_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On May 1, 2026, the Company closed a private placement (“the Private Placement”) pursuant to a Securities Purchase Agreement (the “Purchase Agreement”), dated April 29, 2026, among the Company and certain entities affiliated with Suvretta Capital (each, an “Investor” and collectively, the “Investors”), in which the Company sold to the Investors pre-funded warrants (the “Pre-Funded Warrants”) to purchase an aggregate of 300,000 shares of Common Stock, at an offering price of $99.99999 per Pre-Funded Warrant. The gross proceeds of the Private Placement were approximately $30.0 million","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1827635/000162828026029376/0001628280-26-029376-index.htm","comparable_excerpt":"On May 28, 2026, CitroTech Inc., a Wyoming corporation (the “Company”), entered into Stock Exchange and Stockholders Agreements (the “Exchange Agreements”) with the holders (the “Holders”) of the Company’s outstanding Series A Preferred Stock","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/894556/000168316826004423/0001683168-26-004423-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}